Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)

Purpose To date, it is not clear which anticancer agent is useful in combination with trastuzumab and pertuzumab As the first and second selective regimens for advanced or metastatic breast cancer (AMBC), this multicenter, open-label, phase II trial (JBCRG-M03: UMIN000012232) presents a prespecified...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Toshinari, Kawaguchi, Hidetoshi, Masuda, Norikazu, Kitada, Masahiro, Narui, Kazutaka, Hattori, Masaya, Yoshinami, Tetsuhiro, Matsunami, Nobuki, Yanagihara, Kazuhiro, Kawasoe, Teru, Nagashima, Takeshi, Bando, Hiroko, Yano, Hiroshi, Hasegawa, Yoshie, Nakamura, Rikiya, Kashiwaba, Masahiro, Morita, Satoshi, Ohno, Shinji, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851001/
https://www.ncbi.nlm.nih.gov/pubmed/32833136
http://dx.doi.org/10.1007/s10637-020-00991-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851001/
https://www.ncbi.nlm.nih.gov/pubmed/32833136
http://dx.doi.org/10.1007/s10637-020-00991-6

Ejemplares similares